Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04125719 | PVSRIPO in Combination With Nivolumab in Melanoma(PPD1) | withdrawn | Phase 1 | 0 | Darell BignerOTHER | 1 | Feb 11, 2020 | clinicaltrials |
| NCT03022565 | Vorinostat in Patients With Class 2 High Risk Uveal Melanoma | withdrawn | Early Phase 1 | 0 | University of MiamiOTHER | 0 | Feb 6, 2020 | clinicaltrials |
| NCT02828345 |
| Bio-marker Analysis Using Circulating Tumor Cells in Patients With Melanoma |
| withdrawn |
| — |
| 0 |
| Abramson Cancer Center at Penn MedicineOTHER |
| 0 |
| Feb 5, 2020 |
| clinicaltrials |
| NCT04007588 | A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma | withdrawn | Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 5, 2020 | clinicaltrials |
| NCT03982134 | PDR001 + Panobinostat for Melanoma and NSCLC | withdrawn | Phase 1 | 0 | Muhammad FurqanOTHER | 0 | Oct 4, 2019 | clinicaltrials |
| NCT03111901 | Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer(UVA-AM-002) | withdrawn | Phase 1 / Phase 2 | 0 | William Grosh, MDOTHER | 1 | Jul 12, 2019 | clinicaltrials |
| NCT02300935 | Study of Trametinib and Nab-paclitaxel in Patients With Melanoma | withdrawn | Phase 1 | 0 | SCRI Development Innovations, LLCOTHER | 1 | May 30, 2019 | clinicaltrials |
| NCT03518229 | Pilot Study of Intervention to Reduce Sunburns in Melanoma Survivors | withdrawn | N/A | 0 | University of MinnesotaOTHER | 0 | Apr 17, 2019 | clinicaltrials |
| NCT02068079 | A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma | withdrawn | Phase 1 | 0 | Duke UniversityOTHER | 1 | Jan 30, 2019 | clinicaltrials |
| NCT02306512 | Mohs and Immunofluorescence for Malignant Melanoma In Situ | withdrawn | N/A | 0 | University of MiamiOTHER | 1 | Jan 7, 2019 | clinicaltrials |
| NCT03177941 | Teaching Skin Self-Examination to First-degree Relatives of Melanoma Patients Using Mobile App Technology | withdrawn | N/A | 0 | Northwestern UniversityOTHER | 1 | Nov 16, 2018 | clinicaltrials |
| NCT02763761 | An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo | withdrawn | Phase 2 | 0 | Bristol-Myers SquibbINDUSTRY | 1 | Oct 9, 2018 | clinicaltrials |
| NCT03220009 | Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Oct 3, 2018 | clinicaltrials |
| NCT02447939 | Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma | withdrawn | Phase 1 | 0 | GlaxoSmithKlineINDUSTRY | 0 | Sep 14, 2018 | clinicaltrials |
| NCT03297463 | Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma | withdrawn | Phase 1 / Phase 2 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Aug 1, 2018 | clinicaltrials |
| NCT03326258 | Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Jul 18, 2018 | clinicaltrials |
| NCT02507947 | SPECTAmel: Screening Patients With Melanoma Tumors for Efficient Clinical Trial Access | withdrawn | — | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 0 | Jul 9, 2018 | clinicaltrials |
| NCT02839694 | Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Jul 5, 2018 | clinicaltrials |
| NCT02915666 | A Clinical Trial of Patients With Melanoma | withdrawn | Phase 1 | 0 | University of Texas Southwestern Medical CenterOTHER | 1 | May 15, 2018 | clinicaltrials |
| NCT03282188 | REO13 Melanoma With of Without GM-CSF | withdrawn | Phase 1 / Phase 2 | 0 | University of LeedsOTHER | 0 | May 4, 2018 | clinicaltrials |
| NCT03205722 | The Effectiveness of Nivolumab Monotherapy as First-Line Therapy in Adults With Advanced Melanoma in Germany | withdrawn | — | 0 | Bristol-Myers SquibbINDUSTRY | 0 | Apr 9, 2018 | clinicaltrials |
| NCT02812693 | Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification | withdrawn | Phase 1 / Phase 2 | 0 | Joanne JeterOTHER | 0 | Apr 5, 2018 | clinicaltrials |
| NCT00588263 | Anonymous Testing of Pathology Specimens for BRCA Mutations in Ashkenazi Jewish Individuals Who Have Cancer | withdrawn | — | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 19, 2018 | clinicaltrials |
| NCT00769990 | Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases | withdrawn | Phase 1 / Phase 2 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 0 | Dec 13, 2017 | clinicaltrials |
| NCT01328106 | Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma | withdrawn | Phase 2 | 0 | GlaxoSmithKlineINDUSTRY | 0 | Dec 12, 2017 | clinicaltrials |
| NCT02719015 | Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic Melanoma | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Nov 24, 2017 | clinicaltrials |
| NCT02736123 | Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone | withdrawn | Phase 1 / Phase 2 | 0 | University of PittsburghOTHER | 1 | Sep 20, 2017 | clinicaltrials |
| NCT01833767 | Low-dose Cyclophosphamide and Outpatient IV Interleukin-2 in Metastatic Melanoma | withdrawn | Phase 2 | 0 | Western Regional Medical CenterOTHER | 1 | Aug 24, 2017 | clinicaltrials |
| NCT02663258 | A Study of Anti-PD-1 (Pembrolizumab) Therapy in Metastatic Melanoma (ADAPTeM)(ADAPTeM) | withdrawn | Phase 2 | 0 | Royal Marsden NHS Foundation TrustOTHER | 0 | Aug 1, 2017 | clinicaltrials |
| NCT02489266 | In Vivo Persistence of Adoptively-Transferred TIL Cultured With Akti in People With Metastatic Melanoma | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Jul 27, 2017 | clinicaltrials |
| NCT02210104 | Adoptive Therapy Using Antigen-Specific CD4 T-Cells | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jul 21, 2017 | clinicaltrials |
| NCT01843738 | Radiation Use During Vemurafenib Treatment | withdrawn | Phase 1 | 0 | University of UtahOTHER | 1 | May 24, 2017 | clinicaltrials |
| NCT02400385 | A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma | withdrawn | Phase 2 | 0 | California Pacific Medical Center Research InstituteOTHER | 1 | Feb 1, 2017 | clinicaltrials |
| NCT02661100 | A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients | withdrawn | Phase 1 / Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 0 | Dec 7, 2016 | clinicaltrials |
| NCT02427893 | Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma | withdrawn | Phase 3 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Nov 15, 2016 | clinicaltrials |
| NCT01765556 | A Pharmacokinetics Study to Investigate the Effect of Ketoconazole on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma | withdrawn | Phase 1 | 0 | Hoffmann-La RocheINDUSTRY | 0 | Nov 2, 2016 | clinicaltrials |
| NCT02862145 | Pharmacodynamics Study of MRX34, MicroRNA Liposomal Injection in Melanoma Patients With Biopsy Accessible Lesions(MRX34-102) | withdrawn | Phase 1 / Phase 2 | 0 | Mirna Therapeutics, Inc.INDUSTRY | 0 | Sep 27, 2016 | clinicaltrials |
| NCT01312506 | Collection of Cerebrospinal Fluid and Tumor Tissue in Subjects With Metastatic Melanoma and Controls | withdrawn | — | 0 | University of PittsburghOTHER | 0 | Jul 27, 2016 | clinicaltrials |
| NCT02061007 | Biomarker Correlates of Hypoxia in Metastatic Melanoma | withdrawn | Phase 2 | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 0 | May 9, 2016 | clinicaltrials |
| NCT02065466 | Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases | withdrawn | Phase 1 / Phase 2 | 0 | University of ArizonaOTHER | 1 | Apr 21, 2016 | clinicaltrials |
| NCT02452281 | Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma | withdrawn | Phase 1 / Phase 2 | 0 | Rabih SaidOTHER | 1 | Jan 25, 2016 | clinicaltrials |
| NCT02357732 | Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib | withdrawn | Phase 1 | 0 | University of PittsburghOTHER | 0 | Dec 11, 2015 | clinicaltrials |
| NCT00006126 | Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery | withdrawn | Phase 1 | 0 | Northwestern UniversityOTHER | 0 | Nov 13, 2015 | clinicaltrials |
| NCT00093678 | Celecoxib in Managing Pain, Weight Loss, and Weakness in Patients With Advanced Cancer | withdrawn | N/A | 0 | Eastern Cooperative Oncology GroupNETWORK | 0 | Oct 8, 2015 | clinicaltrials |
| NCT01764009 | Safety and Efficacy of Intramuscular Electrotransfer of Plasmid AMEP in Patients Suffering From Advanced or Metastatic Melanoma(AIMM) | withdrawn | Phase 1 / Phase 2 | 0 | Valerio TherapeuticsINDUSTRY | 2 | Sep 11, 2015 | clinicaltrials |
| NCT02507076 | Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or Sarcoma | withdrawn | N/A | 0 | Albert Einstein College of MedicineOTHER | 1 | Jul 23, 2015 | clinicaltrials |
| NCT01851408 | Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Apr 15, 2015 | clinicaltrials |
| NCT00661336 | A Phase I Trial of Normothermic Isolated Limb Infusion (ILI) With Melphalan Plus Buthionine Sulfoximine (BSO) in Patients With Locally Advanced Malignant Melanoma | withdrawn | Phase 1 | 0 | Duke UniversityOTHER | 1 | Mar 13, 2015 | clinicaltrials |
| NCT01593579 | Autonomic Phenotype Before and After Akt Inhibition | withdrawn | — | 0 | Vanderbilt UniversityOTHER | 1 | Dec 23, 2014 | clinicaltrials |
| NCT01531244 | Isolated Limb Infusion Chemotherapy With Targeted Gene Therapy for Advanced, Unresectable Extremity Melanoma | withdrawn | Phase 1 / Phase 2 | 0 | Washington University School of MedicineOTHER | 0 | Jul 18, 2014 | clinicaltrials |
Data updated 22 days agoSource updated Feb 11, 2020source: clinicaltrials